Osteoarthritis Therapy Market Size, Share, Growth by 2030

The osteoarthritis therapy market is anticipated to expand from US$ 17.36 billion in 2022 to US$ 30.68 billion by 2030, reflecting a compound annual growth rate (CAGR) of 7.4% from 2022 to 2030.

The increasing incidence of osteoarthritis (OA) and the emergence of innovative treatment options that lessen reliance on traditional medications are significant factors driving the growth of the osteoarthritis therapy market. However, product recalls pose challenges to market expansion. Additionally, the development of more effective treatment alternatives is a promising trend that is expected to enhance the osteoarthritis therapy market during the forecast period.

Growth Drivers:

Increasing Incidence of Osteoarthritis Fuels Market Expansion

According to a report from the CDC, osteoarthritis affects over 500 million individuals globally, which is approximately 7% of the global population, making it a leading cause of long-term disability. The condition is particularly common among athletes and individuals who have experienced joint injuries or trauma. Furthermore, women are disproportionately affected, representing 60% of all OA cases worldwide.

The World Health Organization (WHO) indicates that osteoarthritis is more prevalent in older populations. While OA can impact anyone, it is most frequently diagnosed in adults aged 40 and older. The WHO report also highlights that around 73% of individuals over 55 years old live with OA, with 60% being female. In the United States, the CDC estimates that over 32.5 million adults suffer from OA. Consequently, as the prevalence of OA rises, new therapeutic options, including biological therapies, are gaining traction globally. One notable example is platelet-rich plasma (PRP) therapy, which promotes tissue recovery by enhancing the body?s natural healing and repair mechanisms.

Report Segmentation and Scope:

The osteoarthritis therapy market is categorized by therapy type, disease indication, and end user. In terms of therapy type, the market includes Transcutaneous Electrical Nerve Stimulation (TENS), occupational therapy, physical therapy, platelet-rich plasma (PRP) therapy, stromal vascular fraction, prolotherapy, and others. The disease indication segment encompasses knee osteoarthritis, spine osteoarthritis, foot and ankle osteoarthritis, shoulder osteoarthritis, hand osteoarthritis, and others. Regarding end users, the market is divided into hospitals and clinics, specialty clinics, ambulatory surgical centers (ASCs), homecare, and others.



Insights by Therapy Type

The osteoarthritis therapy market is divided into several therapy types, including transcutaneous electrical nerve stimulation (TENS), occupational therapy, physical therapy, platelet-rich plasma, stromal vascular fraction, prolotherapy, and others. In 2022, the physical therapy segment dominated the market share among therapy types. The 'others' segment is projected to experience the fastest growth, with a CAGR of 7.5% during the forecast period. Physical therapies, such as yoga, have been shown to enhance physical function in patients with knee osteoarthritis. Clinical studies indicate that patients receiving physical therapy (PT) for knee osteoarthritis experience greater quality-adjusted life years compared to those treated with glucocorticoid injections. Moreover, physical therapy is not only clinically more effective but also considered a more cost-efficient option.

The 'others' segment is expected to achieve the highest CAGR in the osteoarthritis therapy market. Rehabilitation therapy is another important approach for osteoarthritis, focusing on pain reduction and functionality enhancement. The primary aim of rehabilitation is to alleviate symptoms of knee OA and slow its progression. Future rehabilitation strategies will likely emphasize non-pharmacological management, including exercise, which has been proven to improve quality of life, joint function, muscle strength, and overall performance. Thus, advancements in rehabilitation programs are expected to significantly alleviate osteoarthritis pain, further driving market growth during the forecast period.

Insights by Disease Indication

In 2022, the knee osteoarthritis segment held the largest market share within the disease indication category and is projected to grow at the highest CAGR of 7.7% throughout the forecast period. The National Academy of Sciences reports that knee osteoarthritis (KO) accounts for over 80% of the total disease burden, affecting nearly 19% of American adults aged 45 and older annually. The introduction of innovative products by manufacturers can help alleviate the burden of knee osteoarthritis. For instance, in September 2021, Contura International Ltd launched "Arthrosamid," a new product designed to meet the clinical need for a safe, effective, long-lasting, and minimally invasive treatment for knee OA pain. Therefore, the increasing prevalence of knee OA and the introduction of innovative products aimed at reducing osteoarthritis pain are key drivers of market growth.

Insights by End User

The homecare segment represented the largest market share among end users in 2022. Additionally, the hospitals and clinics segment is expected to register the highest CAGR of 7.5% during the forecast period. A primary strategy for managing arthritis is to reduce excess body weight. Furthermore, hot and cold therapies can restore flexibility in stiff joints, alleviating joint pain. The use of electric blankets or moist heating pads can be beneficial for pain relief, while cold treatments, such as ice packs or frozen vegetable bags, can also provide relief. The availability of these treatment options supports effective management of osteoarthritis at home, contributing to the growth of the homecare segment in the osteoarthritis therapy market.

Regional Analysis:

Geographically, the global osteoarthritis therapy market is divided into North America, Europe, Asia Pacific, South and Central America, and the Middle East and Africa. In 2022, North America held the largest share of the global osteoarthritis therapy market. The Asia Pacific region is projected to exhibit the highest CAGR from 2022 to 2030. Within the North American market, the United States accounts for the largest share. According to the CDC, osteoarthritis is the most prevalent form of arthritis, affecting 32.5 million adults in the US. The economic burden of OA in the US is estimated at US$ 136.8 billion annually, as reported by the Osteoarthritis (OA) Action Alliance. Furthermore, the lifetime risk of developing OA is approximately 50%, with projections indicating that by 2040, around 78 million (26%) adults in the US will be affected.

Moreover, new product approvals targeting non-pharmacological therapies for OA pain are influencing the growth of the osteoarthritis therapy market. In June 2021, CyMedica Orthopedics received FDA approval for the "Intellihab System," a non-invasive treatment modality for knee osteoarthritis pain. This innovative product represents a therapeutic and digital ecosystem designed to address OA pain effectively. Therefore, the introduction of non-pharmacological therapies aimed at reducing reliance on traditional treatments is expected to significantly boost the osteoarthritis therapy market during the forecast period.